Oncophage Study
Purpose of the trial: This study is for patients who are scheduled to have a kidney removed because of cancer. Oncophage is a vaccine made from an individual patient's tumor. Once a patient has had surgery to remove the kidney cancer, a portion of the tumor is sent to the Antigenics laboratory, where the tumor-derived vaccines are made.

Trial sponsor: Antigenics

Randomization: The participant has a 50% chance of receiving the study drug.

Protocol: C-100-12

Phase: III

Enrollment status: Closed

Contact for participation consideration: Jill Bradshaw, RN; (704) 355-9342; Jill.Bradshaw@carolinashealthcare.org